

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

CDK12 Antibody

RRID:AB_2715688

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 11973, RRID:AB_2715688

Antibody Information

URL: http://antibodyregistry.org/AB_2715688

Proper Citation: Cell Signaling Technology Cat# 11973, RRID:AB_2715688

Target Antigen: CDK12

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP

Antibody Name: CDK12 Antibody

Description: This polyclonal targets CDK12

Target Organism: Human, Monkey

Antibody ID: AB_2715688

Vendor: Cell Signaling Technology

Catalog Number: 11973

Alternative Catalog Numbers: 11973S

Record Creation Time: 20250819T214910+0000

Record Last Update: 20250820T001154+0000

Ratings and Alerts

No rating or validation information has been found for CDK12 Antibody.

No alerts have been found for CDK12 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF?? complex for genomic stability. Cell reports, 44(11), 116495.

Polenkowski M, et al. (2023) THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate. iScience, 26(1), 105784.

Dieter SM, et al. (2021) Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell reports, 36(3), 109394.

Sivakumaren SC, et al. (2020) Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell chemical biology, 27(5), 525.

Lv L, et al. (2020) Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. eLife, 9.

Iniguez AB, et al. (2018) EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer cell, 33(2), 202.

Gao Y, et al. (2018) Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell chemical biology, 25(2), 135.

Wu YM, et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 173(7), 1770.